Skip to main
CJC-Ipa Chemical

A broadsheet reading of the CJC-1295 and ipamorelin literature — what the GHRH-plus-GHRP record actually establishes, and where it stops.

The paper behind each numbered claim

Where Are the CJC-1295 Ipamorelin References?

Each paper backs a study fact on this site. None tested the mixed product in a fair human study.

Return to the findingsReview health concerns

What will you find in the paper list?

CJC-1295 was first made to extend the work of a natural brain hormone. Ipamorelin was made for a shorter rise without extra cortisol, a stress hormone. The papers below show you what happened when researchers tested those goals.

Some papers cover one drug. Others study related drugs used together or look at safety across the wider group. Each numbered item names a journal. Its link opens a public medical library entry, which may offer you a short summary or the full paper. A few later papers deal only with urine tests for banned sports drugs.

No paper in the list reports a fair human trial of both drugs together. A citation may support one drug or explain the pairing idea. It can't prove the mixed CJC-1295 Ipamorelin product for you.

Source register

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. ↗
  3. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. ↗
  4. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. ↗
  5. Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. ↗
  6. Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. ↗
  7. Ionescu M, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. ↗
  8. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. ↗
  9. Thomas A, et al. Metabolism of growth hormone releasing peptides. Anal Chem. 2012;84:10252-9. ↗
  10. Thomas A, et al. Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry. J Chromatogr A. 2012;1259:251-7. ↗
  11. Thomas A, et al. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal Bioanal Chem. 2011;401:507-16. ↗
  12. Norman C, et al. Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women. Eur J Endocrinol. 2014;170:121-9. ↗
  13. Sallam HS, Chen JD. The prokinetic face of ghrelin. Int J Pept. 2010;2010:493614. ↗
  14. Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009;19(5):426-431. ↗